Literature DB >> 8745489

[Overexpression of C-erbB3 in transitional cell carcinoma of the ovary].

K Shen1, J Lang, L Guo.   

Abstract

OBJECTIVE: To determine the prevalence of C-erbB3 abnormal protein expression in transitional cell carcinoma of the ovary in our hospital and to analyse the correlation between the overexpression of C-erbB3 protein and prognostic parameters of transitional cell carcinoma of the ovary.
METHODS: Thirty-two transitional cell carcinoma of the ovary and 20 normal ovaries were studied for overexpression of C-erbB3 protein by immunohistochemical staining (IHS), using the monoclonal antibody RJT2 on paraffin sections.
RESULTS: Forty seven percent of 32 samples of transitional cell carcinoma of the ovary showed positive IHS with RJT2, and 39% of 20 normal ovaries showed positive cytoplasmic and membrane staining (P > 0.05). C-erbB3 overexpression did not correlate with age, CA125 levels, histological grade and lymph node metastases, but patients with overexpression of C-erbB3 had a poorer prognosis.
CONCLUSION: Overexpression of C-erbB3 is a common event in transitional cell carcinoma of ovary. Further studies are warranted to clarify the role of C-erbB3 in transitional cell carcinoma of the ovary.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8745489

Source DB:  PubMed          Journal:  Zhonghua Fu Chan Ke Za Zhi        ISSN: 0529-567X


  6 in total

Review 1.  Transitional cell carcinoma of the ovary: a rare case and review of literature.

Authors:  E M Tazi; I Lalya; M F Tazi; Y Ahellal; H M'rabti; H Errihani
Journal:  World J Surg Oncol       Date:  2010-11-14       Impact factor: 2.754

2.  Effects of silibinin on growth and invasive properties of human ovarian carcinoma cells through suppression of heregulin/HER3 pathway.

Authors:  Majid Momeny; Reza Ghasemi; Giovanni Valenti; Mariska Miranda; Ali Zekri; Ghazaleh Zarrinrad; Sepehr Javadikooshesh; Marjan Yaghmaie; Kamran Alimoghaddam; Ardeshir Ghavamzadeh; Seyed H Ghaffari
Journal:  Tumour Biol       Date:  2015-10-19

3.  High incidence of ErbB3, ErbB4, and MET expression in ovarian cancer.

Authors:  Suzy Davies; Anna Holmes; Lesley Lomo; Mara P Steinkamp; Huining Kang; Carolyn Y Muller; Bridget S Wilson
Journal:  Int J Gynecol Pathol       Date:  2014-07       Impact factor: 2.762

Review 4.  EGFR/HER-targeted therapeutics in ovarian cancer.

Authors:  Jason A Wilken; Tayf Badri; Sarah Cross; Rhoda Raji; Alessandro D Santin; Peter Schwartz; Adam J Branscum; Andre T Baron; Adam I Sakhitab; Nita J Maihle
Journal:  Future Med Chem       Date:  2012-03       Impact factor: 3.808

Review 5.  The ERBB3 receptor in cancer and cancer gene therapy.

Authors:  G Sithanandam; L M Anderson
Journal:  Cancer Gene Ther       Date:  2008-04-11       Impact factor: 5.987

6.  Pure Transitional Cell Carcinoma of the Ovary Presenting as Bilateral Complex Cystic Masses in a Premenopausal Woman - Case Report and Review of Literature.

Authors:  Garima Yadav; Vrushti Solanki; Jyotsna Naresh Bharti; Sushma Bharti; Pratibha Singh; Meenakshi Gothwal
Journal:  J Midlife Health       Date:  2019 Jul-Sep
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.